Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dr Pablo F. Céspedes, CAMS Oxford Institute Career Development Fellow, has received funding from NC3Rs to establish a lymphoid organoid and explant hub for researchers across the country.

CAMS Oxford Institute researchers

Mice have long been the preferred model for studying multisystemic immunity. However, accumulated evidence shows that mouse immunology poorly replicates the genetic, biochemical, and physical diversity of humans.

The recent development of lymphoid organoids from tonsils and spleens, by Professor Mark Davis's group at the Stanford University School of Medicine, demonstrates the scientific benefits and predictive power of non-animal, primary human lymphoid organoids. Despite these advantages, broad adoption of these organoids remains challenging due to limited access to fresh human tissue samples and protocols for their use.

At the CAMS Oxford Institute, the Cespedes lab has successfully adopted this novel tonsil organoid technology and developed a second method for investigating lymphocyte self-organisation into ex vivo follicles. Their new system can be primed with recombinant antigens and other growth factors, enabling a wide variety of experimental designs. This approach has replaced the need for genetically modified mouse models, with significant potential to further reduce animal model use.

The award from NC3Rs, made as part of the 2024 non-animal methods infrastructure grants supported with funding from the Department for Science, Innovation & Technology (DSIT), will allow Dr Pablo Cespedes to purchase equipment, consumables and training materials to establish a high throughput facility to generate lymphoid organoids prepared from human tonsil and spleen tissue. This facility should reduce the use of animal models for immunology studies. The aim is to remove barriers to proof-of-principle experiments by providing access to instruments, tissues, recombinant materials, protocols, and hands-on training.

The facility will provide lymphoid organoids for researchers at the University of Oxford and across the UK.